Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 20;7(6):650-5.
doi: 10.7150/jca.13460. eCollection 2016.

miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers

Ya-Ching Lu  1 , Joseph T Chang  2 , Err-Cheng Chan  1 , Yin-Kai Chao  3 , Ta-Sen Yeh  4 , Jinn-Shiun Chen  5 , Ann-Joy Cheng  1
Affiliations
Review

miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers

Ya-Ching Lu et al. J Cancer. .

Abstract

Over the past decade, the emergence of microRNA (miRNA) research has firmly established this molecular family as a key component in cells. MiRNAs, which function as negative gene regulators, participate in multiple biological processes and maintain homeostasis in cells. The dysregulation of miRNA may contribute to numerous human disorders, including cancer. Recently, miR-196 was found to be aberrantly expressed in a wide range of malignant diseases, which suggests that it plays important roles in carcinogenesis. Here, we summarize the current knowledge concerning miR-196 family in cancers. This review includes miR-196 gene structure and aberrant expression in various cancers, and current understanding of numerous functions and regulatory targets of miR-196 in specific cancers. Since miR-196 are consistently found over-expressed in digestive tract cancer tissues, we also reviewed the clinical significance and potential applications of miR-196 in these cancers. We highlight that miR-196 may serve as an emerging cancer biomarker for digestive tract cancers.

Keywords: cancer; clinical application; miR-196; regulatory mechanism..

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Elevation of miR-196b levels in the plasma of patients with digestive tract cancer. (n.s.: no statistical significance compared to normal group Mann-Whitney test, ***: P < 0.001 compared to normal group Mann-Whitney test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;755:843–54. - PubMed
    1. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res. 2011;7171-2:1–8. - PubMed
    1. Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015;15:38. - PMC - PubMed
    1. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;156:546–54. - PMC - PubMed
    1. Li H, Yang BB. Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol Sin. 2013;347:870–9. - PMC - PubMed